ArticleAmerican journal of translational research2026
Diagnostic and prognostic value of combined adiponectin, D-dimer, and Framingham Stroke Profilein patients with isolated vertigo and concurrent cerebral infarction.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic and prognostic value of adiponectin (APN), D-dimer (D-D), and the Framingham Stroke Profile (FSP) in patients with isolated vertigo, and further examine the performance of a combined predictive model.
methodsWe retrospectively analyzed 270 patients with isolated vertigo and 150 healthy controls admitted between March 2022 and March 2025. Based on imaging data, patients were categorized into two groups: isolated vertigo without infarction (n = 184) and isolated vertigo with concurrent cerebral infarction (n = 86). Neurological recovery was assessed using the modified Rankin Scale (mRS). Serum levels of APN and D-D, and FSP scores were measured at admission. Group comparisons, correlation analyses, and Receiver Operating Characteristic (ROC) curve analyses were performed. Diagnostic and prognostic efficacy of the markers was compared using the DeLong test, and a combined model was established.
resultsPatients with vertigo exhibited significantly lower APN levels and higher D-D and FSP scores than controls (all P < 0.001), with more pronounced changes in those with cerebral infarction. APN was the strongest single diagnostic marker (AUC = 0.855), followed by D-D (AUC = 0.821) and FSP score (AUC = 0.816). The combined model achieved the highest diagnostic accuracy (AUC = 0.928; accuracy 89.6%). D-D showed a strong correlation with intracranial atherosclerosis (r = 0.551). For prognosis, D-D was the best individual predictor (AUC = 0.854), but the combined model again outperformed all single markers (AUC = 0.861, P < 0.05).
conclusionsAPN, D-D, and FSP each contribute to the identification of cerebral infarction and the prediction of recovery in patients with isolated vertigo. A combined model integrating all three markers significantly enhanced diagnostic accuracy and prognostic assessment, offering a valuable tool for clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.